|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
WO2012087772A1
(en)
*
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
CA2876689C
(en)
|
2012-06-13 |
2022-04-26 |
Incyte Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
WO2014099697A1
(en)
*
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
3-ester-4-substituted orexin receptor antagonists
|
|
US9643955B2
(en)
|
2012-12-20 |
2017-05-09 |
Merck Sharp & Dohme Corp. |
2-pyridyloxy-3-nitrile-4-substituted orexin receptor antagonists
|
|
ES2639717T3
(es)
*
|
2013-02-07 |
2017-10-30 |
Merck Patent Gmbh |
Derivados de piridazinona macrocíclicos
|
|
JP6483624B2
(ja)
*
|
2013-02-07 |
2019-03-13 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
ピリダジノン−アミド誘導体
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
TWI667233B
(zh)
*
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
HK1231480A1
(zh)
*
|
2014-01-10 |
2017-12-22 |
Aurigene Discovery Technologies Limited |
作为irak4抑制剂的吲唑化合物
|
|
IL311677B2
(en)
|
2014-01-13 |
2025-06-01 |
Aurigene Oncology Ltd |
Bicyclic heterocyclyl derivatives as irak4 inhibitors
|
|
EP3200788B1
(en)
|
2014-09-30 |
2019-09-18 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
US9943516B2
(en)
|
2014-09-30 |
2018-04-17 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
WO2016053772A1
(en)
*
|
2014-09-30 |
2016-04-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
WO2016053771A1
(en)
*
|
2014-09-30 |
2016-04-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
JO3705B1
(ar)
*
|
2014-11-26 |
2021-01-31 |
Bayer Pharma AG |
إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
|
|
EP3233840B1
(en)
|
2014-12-16 |
2018-11-21 |
Eudendron S.r.l. |
Heterocyclic derivatives modulating activity of certain protein kinases
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
DK3286181T3
(da)
|
2015-04-22 |
2021-04-06 |
Rigel Pharmaceuticals Inc |
Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne
|
|
EP3195865A1
(de)
|
2016-01-25 |
2017-07-26 |
Bayer Pharma Aktiengesellschaft |
Kombinationen von irak4 inhibitoren und btk inhibitoren
|
|
WO2016174183A1
(en)
|
2015-04-30 |
2016-11-03 |
Bayer Pharma Aktiengesellschaft |
Combinations of inhibitors of irak4 with inhibitors of btk
|
|
US10435396B2
(en)
|
2016-03-03 |
2019-10-08 |
Bayer Pharma Aktiegesellschaft |
2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
|
|
EP3219329A1
(en)
|
2016-03-17 |
2017-09-20 |
Bayer Pharma Aktiengesellschaft |
Combinations of copanlisib
|
|
CN109071491B
(zh)
|
2016-04-29 |
2020-08-21 |
拜耳医药股份有限公司 |
吲唑的合成
|
|
SI3448848T1
(sl)
|
2016-04-29 |
2024-01-31 |
Bayer Pharma Aktiengesellschaft |
Polimorfna oblika N-(6-(2-hidroksipropan-2-il)-2-(2-(metilsulfonil)etil)-2H-indazol-5-il) -6-(trifluormetil)piridin-2-karboksamida
|
|
SI3464266T1
(sl)
|
2016-06-01 |
2021-12-31 |
Bayer Animal Health Gmbh |
Substituirani indazoli, uporabni pri zdravljenju in preprečevanju alergijskih in/ali vnetnih bolezni pri živalih
|
|
TW202340194A
(zh)
|
2017-02-16 |
2023-10-16 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
CN120267671A
(zh)
|
2017-03-31 |
2025-07-08 |
奥锐金肿瘤有限公司 |
用于治疗血液病的化合物和组合物
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
AU2018350683A1
(en)
|
2017-10-19 |
2020-04-02 |
Bayer Animal Health Gmbh |
Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
|
|
EP4410377A3
(en)
|
2017-10-31 |
2024-11-13 |
Curis, Inc. |
Compounds and compositions for treating hematological disorders
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
GB201801226D0
(en)
|
2018-01-25 |
2018-03-14 |
Redx Pharma Plc |
Modulators of Rho-associated protein kinase
|
|
KR102956194B1
(ko)
|
2018-05-04 |
2026-04-23 |
인사이트 코포레이션 |
Fgfr 억제제의 염
|
|
RS66310B1
(sr)
|
2018-05-04 |
2025-01-31 |
Incyte Corp |
Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
TWI721483B
(zh)
|
2018-07-13 |
2021-03-11 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
AR118043A1
(es)
|
2019-02-11 |
2021-09-15 |
Merck Patent Gmbh |
DERIVADOS DE INDAZOLIL-ISOXAZOL COMO INHIBIDORES DE c-KIT QUINASA
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
CN114585609B
(zh)
*
|
2019-06-27 |
2024-07-30 |
比奥根Ma公司 |
2h-吲唑衍生物及其在疾病治疗中的用途
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
JP2022545542A
(ja)
|
2019-08-30 |
2022-10-27 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
KR102782229B1
(ko)
|
2019-10-02 |
2025-03-20 |
(주)카이노스메드 |
N-(1h-이미다졸-2-일)벤즈아미드 화합물 및 활성 성분으로 이를 포함하는 약학 조성물
|
|
GEP20247679B
(en)
|
2019-10-14 |
2024-10-10 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN114599652B
(zh)
*
|
2019-10-31 |
2024-07-12 |
豪夫迈·罗氏有限公司 |
用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物
|
|
EP4061816A1
(en)
|
2019-11-19 |
2022-09-28 |
F. Hoffmann-La Roche AG |
Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
|
|
CN114761406B
(zh)
|
2019-12-03 |
2024-04-19 |
豪夫迈·罗氏有限公司 |
用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物
|
|
MX2022006691A
(es)
|
2019-12-04 |
2022-09-19 |
Incyte Corp |
Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
|
|
WO2021113479A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
US11866405B2
(en)
|
2020-12-10 |
2024-01-09 |
Astrazeneca Ab |
Substituted indazoles as IRAK4 inhibitors
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
WO2022187303A1
(en)
|
2021-03-03 |
2022-09-09 |
Rigel Pharmaceuticals, Inc. |
A method for treating a disease or condition using a pyrazole compound or formulation thereof
|
|
CA3214747A1
(en)
|
2021-04-08 |
2022-10-13 |
Reinhard Von Roemeling |
Combination therapies for the treatment of cancer
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
CA3217792A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc |
Cdk2 degraders and uses thereof
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
TW202313610A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|
|
EP4361153A4
(en)
|
2021-06-25 |
2025-07-02 |
Korea Res Inst Chemical Tech |
NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその合成
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
ES3075943T3
(en)
|
2022-03-23 |
2026-08-10 |
Rigel Pharmaceuticals Inc |
Pyrimid-2-yl-pyrazole compounds as irak inhibitors
|
|
WO2023191425A1
(ko)
*
|
2022-03-28 |
2023-10-05 |
주식회사 비엔에이치리서치 |
약물의 전기생리학적 스크리닝 방법
|
|
KR102607237B1
(ko)
*
|
2023-06-07 |
2023-11-30 |
주식회사 젠센 |
신규한 트리아졸이 치환된 인다졸 유도체 및 이의 용도
|
|
EP4759807A1
(en)
*
|
2023-08-11 |
2026-06-17 |
Shenzhen Zhongge Biological Technology Co., Ltd. |
Proteolysis targeting chimera compound for degrading irak4 and use thereof
|